Pfizer to buy Medivation in $14 bln deal
Aug 22 (Reuters) - Pfizer Inc said it would buy U.S. cancer drug company Medivation Inc in a deal valued at about $14 billion to boost its oncology portfolio.
Pfizer will offer Medivation shareholders $81.50 per share in cash, a premium of 21.35 percent to the stock's Friday close of $67.16.
Reuters had reported that Pfizer, Sanofi, Merck & Co Inc , Celgene Corp and Gilead Sciences Inc had submitted expressions of interest to acquire Medivation. (Reporting by Ankur Banerjee in Bengaluru; Editing by Don Sebastian)
© Copyright Reuters Ltd. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Reuters Ltd.
